Eli Lilly Q3 2026 Earnings: Mounjaro, Zepbound and the Retatrutide Pipeline
Eli Lilly beat Q3 forecasts and lifted 2026 sales guidance to $91B-$92B. Mounjaro, Zepbound, retatrutide vs. Ozempic, sleep apnea, valuation and our pick.
Eli Lilly beat Q3 forecasts and lifted 2026 sales guidance to $91B-$92B. Mounjaro, Zepbound, retatrutide vs. Ozempic, sleep apnea, valuation and our pick.